Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the “do ut des” paradigm)
Open Access
- 31 July 2006
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 59 (1) , 40-50
- https://doi.org/10.1016/j.critrevonc.2006.02.007
Abstract
No abstract availableKeywords
This publication has 76 references indexed in Scilit:
- Will the dark sky over advanced renal cell carcinoma soon become brighter?European Journal Of Cancer, 2005
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005
- Cancer genes and the pathways they controlNature Medicine, 2004
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- Molecular regulation of vessel maturationNature Medicine, 2003
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002
- Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levelsAnnals of Oncology, 2002
- The Hallmarks of CancerCell, 2000
- Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic modelsEuropean Journal Of Cancer, 1996
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI Journal of the National Cancer Institute, 1990